Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 600 participants.
Also called NCT05309460
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 600 participants
- Sponsor
- Nebraska Methodist Health System
- Registry
-
NCT05309460
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT05309460. Randomized; no masking; primary purpose treatment. Start 2022-06-20 (actual); primary completion 2024-05-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial
- Condition
- Postpartum Preeclampsia
- Condition
- Hypertension in Pregnancy
- Intervention (Drug)
- Labetalol Oral Tablet
- Intervention (Drug)
- NIFEdipine ER
- Lead sponsor
- Nebraska Methodist Health System
Record details
- Record id
cardio:ct-nct05309460- Content hash
74c1a80eecfeef08d69064c5b73f0ef64fef210587a3e4e044a47a9f448074f8